BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) reported today that Dr. Hynda Kleinman has joined RegeneRx’s Medical and Scientific Advisory Board. Dr. Kleinman is the former chief of the Cell Biology Section at the National Institute of Dental and Craniofacial Research, one of the National Institutes of Health in Bethesda Maryland. Dr. Kleinman’s research laboratory first reported on the wound healing effects of Thymosin beta 4 (Tß4), a synthetic version of a naturally occurring molecule that is a major component of RegeneRx’s technology platform and the subject of phase II clinical trials.
